A 42-year-old woman recently diagnosed with rheumatoid arthritis asks the nurse practitioner about disease-modifying antirheumatic drugs (DMARDs). Which of the following statements about DMARDs is INCORRECT?

Choice A reason: DMARDs act on the underlying inflammatory process in rheumatoid arthritis, modifying disease progression. Choice B reason: DMARDs slow or prevent joint damage and improve long-term functional outcomes. Choice C reason: DMARDs are a heterogeneous group, including traditional and biologic agents, administered orally, subcutaneously, or intravenously. Choice D reason: Symptom improvement is typically delayed and may take 6–12 weeks or longer after starting DMARD therapy; expecting improvement in 3 weeks is inaccurate.